Seminars in Arthritis and Rheumatism
Volume 39, Issue 2 , Pages 116-122 , October 2009

Effect of Tumor Necrosis Factor Alpha Inhibition on Bone Density and Turnover Markers in Patients with Rheumatoid Arthritis and Spondyloarthropathy

  • Cheryl Barnabe, MD, FRCPC

      Affiliations

    • Resident, Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    • Corresponding Author InformationAddress reprint requests to Cheryl Barnabe, MD, FRCPC, University of Calgary, Division of Rheumatology, 1301 3350 Hospital Dr NW, Calgary, Alberta, Canada T2N 2T9
    • ,
  • David A. Hanley, MD, FRCPC

      Affiliations

    • Professor, Departments of Medicine, Community Health Sciences, and Oncology, Division of Endocrinology and Metabolism, University of Calgary, Calgary, Alberta, Canada

References 

  1. Sinigaglia L, Varenna M, Girasole G, Bianchi G. Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am. 2006;32:631–658
  2. Romas E, Gillespie MT. Inflammation-induced bone loss: can it be prevented?. Rheum Dis Clin North Am. 2006;32:759–773
  3. Henderson NK, Sambrook PN. Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone. Curr Opin Rheumatol. 1996;8:365–369
  4. Rosen CJ. Postmenopausal osteoporosis. New Engl J Med. 2005;353:595–603
  5. Woolf AD. An update on glucocorticoid-induced osteoporosis. Curr Opin Rheumatol. 2007;19:370–375
  6. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028–2039
  7. Maricic M. New and emerging treatments for osteoporosis. Curr Opin Rheumatol. 2007;19(4):364–369
  8. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006;33:2398–2408
  9. Maksymowych WP, Inman RD, Gladman D, Thomson G, Stone M, Karsh J, et al. The Spondyloarthritis Research Consortium of Canada (SPARCC) Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-α directed therapies in the treatment of spondyloarthritis. J Rheumatol. 2003;30:1356–1363
  10. Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, et al. Long term effects of Infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;epub
  11. Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther. 2007;9(3):R61
  12. Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M. Bone metabolism changes during anti-TNF-α therapy in patients with active rheumatoid arthritis. Ann NY Acad Sci. 2006;1069:420–427
  13. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:1495–1499
  14. Lange U, Teichmann J, Muller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-α antibody: a prospective open-label pilot study. Rheumatology. 2005;44:1546–1548
  15. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment. Ann Rheum Dis. 2005;64:1137–1140
  16. Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α. Ann Rheum Dis. 2003;62:347–349
  17. Demis E, Roux C, Breban M, Dougados M. Infliximab in spondyloarthropathy—influence on bone density. Clin Exp Rheumatol. 2002;20(6 Suppl 28):S185–S186
  18. Gengenbacher M, Sebald H-J, Villiger PM, Hofstetter W, Seitz M. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2007;Epub
  19. Vis M, Wolbink GJ, Lodder MC, Kostense PJ, van de Stadt RJ, de Koning MHMT, et al. Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum. 2003;48(10):2996–3000
  20. Hermann J, Mueller T, Fahrleitner A, Dimai HP. Early onset and effective inhibition of bone resorption in patients with rheumatoid arthritis treated with the tumour necrosis factor alpha antibody infliximab. Clin Exp Rheum. 2003;21:473–476
  21. Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T, Nagafusa T, et al. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology. 2006;45:761–764
  22. Ziolkowska M, Kurowska M, Radzikowska A, Luszcykiewicz G, Wiland P, Dziewczopolski W, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment. Arthritis Rheum. 2002;46(7):1744–1753
  23. Toussirot E, Wendling D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol. 2007;19(4):340–345
  24. Saidenberg-Kermanac'h N, Corrado A, Lemeiter D, deVernejoul MC, Boissier MC, Cohen-Solal ME. TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone. 2004;35(5):1200–1207
  25. Visvanathan S, Marini JC, Smolen JS, St. Clair WE, Pritchard C, Shergy W, et al. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol. 2007;34:1465–1474
  26. Kim T-H, Stone M, Payne U, Zhang X, Ionescu M, Lobanok T, et al. Cartilage biomarkers in ankylosing spondylitis (relationship to clinical variables and treatment response). Arthritis Rheum. 2005;52(3):885–891
  27. Korczowska I, Hrycaj P, Lacki JK. [Change in biomarkers of osteoporosis in rheumatoid arthritis patients treated with infliximab]. Pol Arch Med Wewn. 2004;111(6):673–678
  28. Ostanek L, Pawlik A, Brzosko I, Vrzosko M, Sterna R, Drozdzik M, et al. The urinary excretion of pyridinoline and deoxypyridinoline during rheumatoid arthritis therapy with infliximab. Clin Rheumatol. 2003;23:214–217

 Cheryl Barnabe has no conflicts of interest to disclose.

 David Hanley claims Amgen as support, clinical trials of Denosumab; and serves on the Canadian advisory board.

PII: S0049-0172(08)00084-X

doi: 10.1016/j.semarthrit.2008.04.004

Seminars in Arthritis and Rheumatism
Volume 39, Issue 2 , Pages 116-122 , October 2009

Article Tools